Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFN-γ) in type 1 diabetes mellitus nephropathy

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 1, 2012, Pages 167-174

  Ellina, Olga ^a   Chatzigeorgiou, Antonios ^a   Kouyanou, Sophia ^b   Lymberi, Maria ^a   Mylona Karagianni, Christina ^a   Tsouvalas, Emmanouil ^a   Kamper, Elli F ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Connective tissue growth factor; Diabetic nephropathy (DN); Extracellular matrix (ECM); Glycosaminoglycans (GAGs); Inflammation; Type 1 diabetes mellitus (T1DM)

Indexed keywords

CD40 ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; GAMMA INTERFERON; GLYCOSAMINOGLYCAN; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

ADOLESCENT; ALBUMINURIA; ANGIOGENESIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SCHOOL CHILD; SPECTROPHOTOMETRY;

ANTIGENS, CD40; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; INTERFERON-GAMMA; MALE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857856742     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.881     Document Type: Article

References (52)

1. Daneman D. Type 1 diabetes. Lancet 2006;367:847-58. (Pubitemid 43363372)
2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53. (Pubitemid 41817713)
3. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003;14:1358-73. (Pubitemid 36519197)
4. Poplawska-Kita A, Mierzejewska-Iwanowska B, Szelachowska M, Siewko K, Nikolajuk A, Kinalska I, et al. Glycosaminoglycans urinary excretion as a marker of the early stages of diabetic neph-ropathy and the disease progression. Diabetes Metab Res Rev 2008;24:310-7. (Pubitemid 351802796)
5. Abaterusso C, Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol 2006;5:211-22. (Pubitemid 44166672)
6. Yokoyama H, Sato K, Okudaira M, Morita C, Takahashi C, Suzuki D, et al. Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy. Kidney Int 1999;56:650-8. (Pubitemid 29353164)
7. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest 1997;100:S67-75. (Pubitemid 28009550)
8. Joladarashi D, Salimath PV, Chilkunda ND. Diabetes results in structural alteration of chondroitin sulfate/dermatan sulfate in the rat kidney: effects on the binding to extracellular matrix components. Glycobiology 2011;21:960-72.
9. Schaefer L, Raslik I, Grone HJ, Schonherr E, Macakova K, Ugorcakova J, et al. Small proteoglycans in human diabetic neph-ropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. FASEB J 2001;15:559-61.
10. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010;5:1420-8.
11. Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Tsunematsu H, et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 2011;121:3343-56.
12. Mason RM. Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal 2009;3:95-104.
13. Mylona-Karayanni C, Gourgiotis D, Bossios A, Kamper EF. Oxidative stress and adhesion molecules in children with type 1 diabetes mellitus: a possible link. Pediatr Diabetes 2006;7:51-9. (Pubitemid 43732642)
14. Khuu HM, Robinson CA, Goolsby K, Hardy RW, Konrad RJ. Evaluation of a fully automated high-performance liquid chro-matography assay for hemoglobin A1c. Arch Pathol Lab Med 1999;123:763-7. (Pubitemid 29409536)
15. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986;883: 173-7. (Pubitemid 16027978)
16. Baici A, Horler D, Moser B, Hofer HO, Fehr K, Wagenhauser FJ. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol Int 1992;12:81-8.
17. Nelson A, Berkestedt I, Schmidtchen A, Ljunggren L, Bodelsson M. Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma. Shock 2008;30:623-7.
18. Taylor KR, Gallo RL. Glycosaminoglycans and their proteogly-cans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006;20:9-22. (Pubitemid 43100470)
19. Campo GM, Avenoso A, D'Ascola A, Campo S, Ferlazzo AM, Sama D, et al. Purified human plasma glycosaminoglycans limit oxidative injury induced by iron plus ascorbate in skin fibroblast cultures. Toxicol In Vitro 2005;19:561-72. (Pubitemid 40719532)
20. Calatroni A, Vinci R, Ferlazzo AM. Characteristics of the interactions between acid glycosaminoglycans and proteins in normal human plasma as revealed by the behaviour of the protein-poly-saccharide complexes in ultrafiltration and chromatographic procedures. Clin Chim Acta 1992;206:167-80.
21. Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006;55:480-6. (Pubitemid 43343279)
22. Broekhuizen LN, Mooij HL, Kastelein JJ, Stroes ES, Vink H, Nieuwdorp M. Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease. Curr Opin Lipidol 2009;20:57-62.
23. Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007;116:1896-906. (Pubitemid 350287085)
24. Kamper M, Tsimpoukidi O, Chatzigeorgiou A, Lymberi M, Kamper EF. The antioxidant effect of angiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats. Transl Res 2010;156:26-36.
25. Kahaly G, Hansen C, Otto E, Forster G, Beyer J, Hommel G. Diabetic microangiopathy and urinary glycosaminoglycans. Exp Clin Endocrinol Diabetes 1997;105:145-51. (Pubitemid 27289428)
26. Gartner K. Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (c57bl/6j db/db and c57bl/ksj db/db). Diabetologia 1978;15:59-63. (Pubitemid 8363627)
27. Hansen C, Irmscher AK, Kuhlemann K, Beyer J, Kahaly G. Insulin-dependent diabetes mellitus and glycosaminoglycans. Horm Metab Res 1995;27:555-8. (Pubitemid 26022763)
28. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
29. De Muro P, Fresu P, Formato M, Tonolo G, Mameli M, Maioli M, et al. Urinary glycosaminoglycan and proteoglycan excretion in normoalbuminuric patients with type 1 diabetes mellitus. J Nephrol 2002;15:290-6. (Pubitemid 34830537)
30. De Muro P, Fresu P, Tonolo G, Maioli M, Cherchi GB, Murgia A, et al. A longitudinal evaluation of urinary glycosaminogly-can excretion in normoalbuminuric type 1 diabetic patients. Clin Chem Lab Med 2006;44:561-7. (Pubitemid 43735627)
31. Chatzigeorgiou A, Harokopos V, Mylona-Karagianni C, Tsouvalas E, Aidinis V, Kamper EF. The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time. Ann Med 2010;42:426-38.
32. Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E. CD40/CD40L signaling and its implication in health and disease. Biofactors 2009;35:474-83.
33. Chatzigeorgiou AE, Lembessis PE, Mylona-Karagianni CF, Tsouvalas EA, Diamanti-Kandarakis E, Kamper EF. CD40 expression and its association with low-grade inflammation in a Greek population of type 1 diabetic juveniles: evidence for differences in CD40 mRNA isoforms expressed by peripheral blood mono-nuclear cells. Exp Clin Endocrinol Diabetes 2009;118:38-46.
34. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 2008;45:1-16.
35. Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant 2005;20:2601-4. (Pubitemid 41672253)
36. Chiarelli F, Cipollone F, Mohn A, Marini M, Iezzi A, Fazia M, et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 2002;25:1829-34. (Pubitemid 41071095)
37. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995;47:935-44.
38. Tanaka T, Kuroiwa T, Ikeuchi H, Ota F, Kaneko Y, Ueki K, et al. Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injury. J Am Soc Nephrol 2002;13:2488-96.
39. Kuroiwa T, Lee EG, Danning CL, Illei GG, McInnes IB, Boumpas DT. CD40 ligand-activated human monocytes amplify glom-erular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms. J Immunol 1999;163:2168-75. (Pubitemid 29382224)
40. Kairaitis L, Wang Y, Zheng L, Tay YC, Harris DC. Blockade of CD40-CD40 ligand protects against renal injury in chronic pro-teinuric renal disease. Kidney Int 2003;64:1265-72. (Pubitemid 37153791)
41. Twigg SM, Cooper ME. The time has come to target connective tissue growth factor in diabetic complications. Diabetologia 2004;47:965-8. (Pubitemid 38918153)
42. Tam FW, Riser BL, Meeran K, Rambow J, Pusey CD, Frankel AH. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 2009;47:37-42.
43. Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R, et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic neph-ropathy. Diabetes Care 2006;29:83-8. (Pubitemid 44033436)
44. Nguyen TQ, Tarnow L, Jorsal A, Oliver N, Roestenberg P, Ito Y, et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 2008;31:1177-82.
45. Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D, et al. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab 2008;93:1893-900. (Pubitemid 351656535)
46. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004;25:971-1010. (Pubitemid 39657775)
47. Hovind P, Tarnow L, Oestergaard PB, Parving HH. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl 2000;75: S56-61. (Pubitemid 30205441)
48. Mironidou-Tzouveleki M, Tsartsalis S, Tomos C. Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus. Curr Drug Targets 2011; 12:107-14.
49. Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007;71:637-45. (Pubitemid 46494557)
50. Sato W, Kosugi T, Zhang L, Roncal CA, Heinig M, Campbell-Thompson M, et al. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab Invest 2008;88:949-61.
51. Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 2002;16:219-21.
52. Wu CC, Chen JS, Lu KC, Chen CC, Lin SH, Chu P, et al. Aberrant cytokines/chemokines production correlate with protei-nuria in patients with overt diabetic nephropathy. Clin Chim Acta 2010;411:700-4.